KRAS and metastatic malignant neoplasm in the lymph nodes: In addition, ACY1 expression levels were lower in patients with KRAS mutation but no lymph node metastasis (group B) than in group C. The expression levels were lowest in patients without lymph node metastasis and KRAS mutation (group A).